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Summary
Background Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of 
cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 
55·7 months [SD 31·4]) for participants with Lynch syndrome enrolled into a randomised trial of daily aspirin versus 
placebo. This report completes the planned 10-year follow-up to allow a longer-term assessment of the effect of taking 
regular aspirin in this high-risk population.
Methods In the double-blind, randomised CAPP2 trial, 861 patients from 43 international centres worldwide 
(707 [82%] from Europe, 112 [13%] from Australasia, 38 [4%] from Africa, and four [<1%] from The Americas) with 
Lynch syndrome were randomly assigned to receive 600 mg aspirin daily or placebo. Cancer outcomes were monitored 
for at least 10 years from recruitment with English, Finnish, and Welsh participants being monitored for up to 
20 years. The primary endpoint was development of colorectal cancer. Analysis was by intention to treat and per 
protocol. The trial is registered with the ISRCTN registry, number ISRCTN59521990.
Findings Between January, 1999, and March, 2005, 937 eligible patients with Lynch syndrome, mean age 45 years, 
commenced treatment, of whom 861 agreed to be randomly assigned to the aspirin group or placebo; 
427 (50%) participants received aspirin and 434 (50%) placebo. Participants were followed for a mean of 10 years 
approximating 8500 person-years. 40 (9%) of 427 participants who received aspirin developed colorectal cancer 
compared with 58 (13%) of 434 who received placebo. Intention-to-treat Cox proportional hazards analysis 
revealed a significantly reduced hazard ratio (HR) of 0·65 (95% CI 0·43–0·97; p=0·035) for aspirin versus 
placebo. Negative binomial regression to account for multiple primary events gave an incidence rate ratio of 0·58 
(0·39–0·87; p=0·0085). Per-protocol analyses restricted to 509 who achieved 2 years’ intervention gave an HR of 
0·56 (0·34–0·91; p=0·019) and an incidence rate ratio of 0·50 (0·31–0·82; p=0·0057). Non-colorectal Lynch 
syndrome cancers were reported in 36 participants who received aspirin and 36 participants who received placebo. 
Intention-to-treat and per-protocol analyses showed no effect. For all Lynch syndrome cancers combined, the 
intention-to-treat analysis did not reach significance but per-protocol analysis showed significantly reduced 
overall risk for the aspirin group (HR=0·63, 0·43–0·92; p=0·018). Adverse events during the intervention phase 
between aspirin and placebo groups were similar, and no significant difference in compliance between 
intervention groups was observed for participants with complete intervention phase data; details reported 
previously.
Interpretation The case for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.
Funding Cancer Research UK, European Union, MRC, NIHR, Bayer Pharma AG, Barbour Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
In 1988, Kune and colleagues reported an apparent 
protective effect of aspirin and other non-steroidal anti-
inflammatory drugs in a colon cancer case-control study.1 
In subsequent years, over 100 observational studies have 
confirmed the cancer preventive properties of aspirin.2,3 A 
series of adenoma prevention trials reported a significant 
but modest effect of aspirin on new polyp formation.4 
Reviews by Rothwell and colleagues of long-term cancer 
outcomes among participants in trials of the cardio-
vascular benefits of aspirin revealed a consistent pattern 
of significant reductions in cancer incidence and mortality 
among those randomly assigned to aspirin, following a 
delay of around 3–5 years.5,6 The Women’s Health Study7 
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randomly assigned over 18 000 women to alternate day 
100 mg aspirin or vitamin E supplement. Intervention 
over 10 years showed no effect on cancer incidence. A 
subsequent post-trial review up to 18 years revealed a 
significantly lower incidence of colorectal cancer in those 
randomly assigned to aspirin.8
The Cancer Prevention Programme (CaPP), originally 
called the Concerted Action Polyposis Prevention (CAPP) 
project, was launched in 1993 to investigate therapeutic 
prevention in those with a proven genetic predisposition 
to colorectal and other cancers. CAPP19 focused on 
adolescents with familial adenomatous polyposis.9 
CAPP2,10 which began in 1999, focused on people with 
Lynch syndrome, formerly known as hereditary non-
polyposis colon cancer, which results from pathogenic 
variants in one of the DNA mismatch repair genes.11 
In both trials, the potential cancer preventives were 
aspirin and resistant starch and a factorial design was 
used; in CAPP2, participants received 600 mg enteric-
coated aspirin or placebo and 30 g of Novelose, a resistant 
starch, or placebo corn starch, daily. Recruits could opt 
to be randomly assigned for a single agent only. If a 
participant agreed to be randomly assigned for aspirin, 
recruits were treated for 2 years with aspirin or placebo; 
after a formal review, the design was adapted to allow 
recruits to consent to continue for a further 2-year period.
When participants had completed this intervention 
phase, data analysis revealed no significant impact 
on neoplasia which combined colorectal adenoma 
and carcinoma formation.10 At that stage, there were 
20 diagnosed colorectal cancers.10 The protocol had 
anticipated a delayed effect on cancer incidence as is 
evident from epidemiological studies in the general 
population12 and provided for follow-up to 10 years. 
When the first recruits reached their 10-year follow-up 
(mean follow-up of 4 years 7 months), intention-to-treat 
analysis showed a non-significant protective effect on 
colorectal cancer in the aspirin limb compared with 
placebo11 (hazard ratio [HR]=0·63, 95% CI 0·35–1·13; 
p=0·12) with a similar result for all Lynch syndrome 
cancers. Per-protocol analysis was restricted to those 
who took aspirin or placebo for the defined minimum 
2-year intervention period. This showed significant 
protection against colorectal cancer (HR=0·41, 95% CI 
0·19–0·86; p=0·02) and a similar reduction for all 
Lynch syndrome cancers (HR=0·45, 95% CI 0·26–0·79; 
p=0·005).11 We now report the planned 10-year analysis, 
in which all participants were beyond the 10-year 
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Research in context
Evidence before this study
There is extensive evidence from case-control studies, 
epidemiology, polyp prevention studies, and long-term review 
of historical aspirin cardiovascular prevention trials that regular 
intake of aspirin (acetyl salicylic acid) and other non-steroidal 
anti-inflammatory drugs over long periods is associated with 
reduced incidence of colorectal and other cancers. Two trials 
explored the protective effects of aspirin with cancer as a 
primary endpoint; the Women’s Health Study showed no effect 
of alternate day 81 mg aspirin up to study end at 10 years, 
but a subsequent reduction in colorectal cancer in the second 
decade. The CAPP2 Study randomised 861 carriers of hereditary 
cancer, Lynch syndrome, average age 42 years, to 600 mg 
aspirin or 30 g resistant starch, or both in a factorial design. 
There was no effect at the end of intervention (average 
2·5 years) but there was a significant per-protocol protective 
effect of the aspirin at an average of 4·6 years follow-up.
Added value of this study
The mechanisms of action of aspirin of relevance to colorectal 
cancer prevention, including for Lynch syndrome, are unknown, 
thus there is no insight into the time that the intervention 
takes to come into full effect or the period over which a time-
limited intervention will allow protection. By monitoring 
people with known intervention and disease status, this study 
examines the magnitude of the effect and provides some 
indications as to the magnitude of the long-term effect.
The cancer histories of all participants in CAPP2 were reviewed 
where possible up to the planned 10-year follow-up and a 
subset in three countries was followed via national registries 
for up to 20 years. Aspirin prescription ended in 2007 at the 
latest. Intention-to-treat Cox proportional hazards analysis 
showed that aspirin protected against the primary endpoint of 
colorectal cancer (HR=0·65 [95% CI 0·43–0·97], p=0·035). 
Negative binomial regression, considering all primary cancer 
diagnoses in the cancer spectrum of Lynch syndrome found 
similar evidence of aspirin protection (incidence rate ratio 0·58, 
95% CI 0·39–0·87, p=0·0085). For those who took aspirin for 
the planned minimum 2 years, the effect was similar; HR 0·56, 
CI 0·34–0·91, p=0·019.
There were half as many endometrial cancers in the aspirin 
group but, overall, non-colorectal cancer Lynch syndrome 
cancers were not significantly different in the longer follow-up. 
In the second decade, there was some evidence of a decline in 
non-Lynch syndrome cancers that did not reach significance.
Implications of all the available evidence
Two standard aspirins per day for 2 years results in a significant 
reduction in colorectal cancer incidence in Lynch syndrome 
carriers, which persists for over a decade but does not become 
apparent until about 5 years from commencement. During 
intervention, serious adverse events did not differ significantly 
from the placebo group in this relatively young group. 
The ongoing CaPP3 Study is a dose non-inferiority trial which 
will inform optimal doses for cancer prevention versus adverse 
events. There is now a strong case for prescribing aspirin to 
young adult carriers of a germline DNA mismatch repair gene 
defect.
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anniversary of their recruitment; this includes the period 
in which the participant was taking the agent. In 
addition, we comple mented these data through access to 
the National Cancer Registration & Analysis Service via 
Public Health England, which provided robust cancer 
data for the English and Welsh recruits up to 20 years; 
equivalent data was obtained for the Finnish participants 
over the same time period.
Methods
Study design and participants
Between January, 1999, and March, 2005, 937 (87%) of 
1071 assessed carriers of Lynch syndrome started inter-
vention in the CAPP2 study. Eligible patients were 
older than 25 years of age and were proven carriers of 
a pathological mismatch-repair mutation (ie, genetic 
diagnosis) or were members of a family that met the 
Amsterdam diagnostic criteria and had a personal 
history of a cured Lynch syndrome neoplasm but a 
largely intact colon (ie, clinical diagnosis). Trial design 
and randomisation blocks have been described previously 
as has a detailed description of participant charac-
teristics;11 a summary of some of the characteristics of the 
participants is shown in the appendix (p 8). All data 
relating to participants, their random assignment and 
all clinical outcomes in the trial were collected by the 
local clinical management centre for each participant 
and then sent to the CAPP2 Offices at Newcastle 
University, UK, where the dedicated CAPP2 study team 
maintained the information in a TrakGene database. 
These data were then linked to study number, anonymised, 
and sent to the University of Leeds (DTB and FE) for 
statistical analysis. Participants consented in writing to 
have their health records followed for 10 years. The study 
had a pre-planned design for 10-years’ follow-up and at the 
time of this analysis, the last enrolled partici pant had 
reached the 10-year threshold. All participants consented 
to long-term follow-up at recruitment and con sent was 
refreshed in the later stages of the study.
Randomisation and masking
Briefly, of the 937 participants, 427 were randomly 
assigned to 600 mg aspirin and 434 to aspirin placebo 
(hereafter placebo; figure 1). The remaining recruits were 
not randomly assigned for the aspirin inter vention, 
having opted not to participate in this part of the study 
(n=76, mostly owing to perceived aspirin sensitivity or 
history of peptic ulceration). All participants were also 
separately randomly assigned to resistant starch or 
resistant starch placebo intervention in a 2 × 2 factorial 
design. Details of the starch randomisation and outcomes 
were reported in 2012,13 and an update is in preparation 
(J Burn; personal communication). Participants and 
investigators were masked to intervention allocation. 
Participants and their clinicians were informed of their 
randomisation category at their 10-year review or later 
when contact was achieved.
Procedures
Recruits received intervention over 2 years with an option 
to continue for a further 2 years. We also included data 
from analysis beyond the 10-year period and up to 20 years 
of follow-up for participants resident in England or 
Wales. For these participants, cancer history was assessed 
by means of national cancer registration information 
made available by Public Health England. Similarly, all 
participants in Finland are monitored centrally, and long-
term cancer information was available for these partici-
pants from the Finnish Lynch syndrome registry. For 
the analysis between 10 and 20 years of follow-up, we 
combined information for 360 participants from England, 
Finland, and Wales.
Details of adenoma recurrence, adverse events during 
and post-intervention, and compliance (ie, proportion of 
scheduled tablets taken during the intervention phase) 
have been described previously.11
Outcomes
The primary outcome of the CAPP2 study was the num-
ber, size, and histological stage of colorectal carcinomas 
found after a minimum of 2 years’ intervention with 
aspirin. Secondary clinical outcomes were the size and 
number of adenomas and of other Lynch syndrome-
related cancers.
This analysis focused on the 861 CAPP2 study par-
ticipants randomly assigned to 600 mg aspirin (n=427) 
or placebo (n=434) from the date of entry until the latest 
date for which we had information about cancer status, 
often corresponding to the date of last surveillance 
attendance and, for recruits in England, Finland, and 
Wales, supplemented with passive recording of cancer 
registration. The analysis included Lynch syndrome 
cancer diagnoses; those that occurred during the 
intervention phase and subsequent to exit from the 
intervention phase. Designation of a reported diagnosis 
as being within the Lynch syndrome cancer spectrum 
was a clinical assessment, masked to intervention; 
endometrial, ovarian, pancreatic, small bowel, gall blad-
der, ureter, stomach, and kidney cancers and cancer of 
the brain were included.14 Adverse events during the 
intervention phase between aspirin and placebo groups 
were reported previously.11
Statistical analysis
Power calculations suggested that to detect a 40% reduc-
tion in cancer risk among those taking aspirin with 
90% power at a 0·05 significance level, about 100 cancer 
diagnoses post-recruitment were required, indicating 
approximately 1000 recruits and a 10-year follow-up. In 
total, 937 eligible patients with Lynch syndrome, mean 
age 45 years, commenced treatment, of which 861 agreed 
to be randomly assigned to the aspirin group or placebo 
and the mean intervention period was 2·5 years. When 
participants had completed this inter vention phase, data 
analysis revealed no significant effect on neoplasia which 
For more on TrakGene 
databases see https://www.
trakgene.com/
See Online for appendix
For the protocol see http://www.
CaPP3.org
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combined colorectal adenoma and carcinoma formation.10 
At that stage, there were 20 diagnosed colorectal cancers.10 
The protocol had anticipated a delayed effect on cancer 
incidence as is evident from epidemiological studies in 
the general population12 and provided for follow-up to 
10 years. When the first recruits reached their 10-year 
follow-up (mean follow-up of 4 years 7 months), inten-
tion-to-treat analysis showed a non-significant protective 
effect on colorectal cancer in the aspirin group compared 
with placebo with a similar result for all Lynch syndrome 
cancers.11 Per-protocol analysis was restricted to those 
who took aspirin or placebo for the defined minimum 
2-year intervention period. This showed significant 
protection against colorectal cancer and a similar 
reduction for all Lynch syndrome cancers.11
Intention-to-treat analyses were done (ie, according to 
aspirin randomisation; aspirin or placebo). However, 
as the intention of this trial was to test the efficacy of 
2-year intervention with aspirin, we also did a per-
protocol analysis that was restricted to those participants 
who achieved the full 2-year intervention. Participants 
were provided with two 300 mg tablets daily over the first 
2 years of the intervention phase and the numbers of 
aspirin (or placebo tablets) remaining were recorded. 
At clinic visits during the intervention period, each 
participant was asked to show the aspirin (or placebo) 
remaining, this number was recorded to allow estimation 
of the number of tablets taken. Participants whose study 
records indicated having taken at least 1400 tablets were 
considered as per protocol.
Two analytical approaches were used: time to first 
occurrence of colorectal cancer (our primary endpoint) 
was examined by means of life-table methods and Cox 
proportional hazards; and investigation of multiple primary 
cancers at the same anatomical site or multiple anatomical 
sites, a feature of Lynch syndrome, by means of negative 
binomial modelling which considers the complete Lynch 
syndrome cancer history since randomisation. Previously, 
we had applied Poisson regression but analysis of this 
extended dataset indicated over-dispersion, so we have 
applied negative binomial regression.11
For life-table analysis and Cox proportional hazards 
analysis, end of follow-up was determined as the time 
to first diagnosis of colorectal cancer (or other Lynch 
syndrome cancer, as appropriate), if the participant was 
diagnosed with cancer following random assignment, or 
the last recorded date at which clinical status was known. 
For the negative binomial regression analysis, exposure 
time was calculated from randomisation until the date 
of last known clinical status, or 10 years if this came 
earlier (20 years if resident in England, Finland, or 
Wales). Analyses were further done as intention to treat 
(ie, intervention assigned at randomisation) and per 
protocol. Beyond 10 years, cancer diagnosis follow-up 
data from England and Wales were obtained from Public 
Health England and their Welsh counterparts (see 
appendix p 3); all data released by Public Health England 
was with the approval of their Office for Data Release 
and within the policy and legal frameworks for the use of 
patient data collected by the National Cancer Registration 
and Analysis Service. Data from the Finnish national 
registry maintained by the Department of Surgery, 
Central Finland Healthcare District, Jyväskylä were 
accessed similarly (see appendix p 3).
Sex-adjusted and age-adjusted hazard ratio (HR) 
estimates and 95% CIs were calculated by means of Cox 
Figure 1: Trial profile 
CRC=colorectal cancer. LS Ca=Lynch syndrome associated cancers.
58 followed during intervention 
period only
3 participants had 3 CRCs
2 participants had 2 other LS Ca
0 participants had non-LS Ca 
427 allocated to 600 mg aspirin 434 allocated to  placebo
 861 randomised to aspirin or placebo
937 participants commenced intervention
 76 randomised only for resistant starch
369 followed up to 10 years
27 participants had 29 CRCs
25 participants had 31 other LS Ca
31 participants had 38 non-LS Ca 
67 followed during intervention 
period only
0 participants had CRCs
4 participants had 4 other LS Ca
2 participants had 2 non-LS Ca
367 followed up to 10 years
43 participants had 51 CRCs
29 participants had 30 other LS Ca
28 participants had 35 non-LS Ca 
189 followed up for 10–20 years
10 participants had 10 CRCs
9 participants had 9 other LS Ca
5 participants had 6 non-LS Ca
171 followed up for 10–20 years
15 participants had 20 CRCs
3 participants had 4 other LS Ca
12 participants had 14 non-LS Ca
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proportional hazard models, and Kaplan-Meier curves 
were used to assess non-parametrically the outcome dif-
ferences between the aspirin and placebo groups; these 
adjustments were deemed desirable given the variation of 
cancer risk with age and the different spectrum of cancer 
in females and males. The assumption of proportional 
hazard was tested by means of Schoenfeld residuals. Sex-
adjusted and age-adjusted incidence rate ratios were 
calculated by means of negative binomial regression to 
estimate the effect of aspirin from log-linear models 
for the number of primary cancers diagnosed after 
randomisation and until the last follow-up.
A secondary analysis examined the incidence of 
non-colorectal Lynch syndrome cancers. A final analysis 
examined the total burden of Lynch syndrome-related 
cancers. In keeping with the original sample size 
calculations, all p values were two-sided. All analyses 
were carried out in Stata (version 14).
The trial is registered with the ISRCTN registry, 
number ISRCTN59521990.
Role of the funding source
Neither the funders nor the sponsors of the study had any 
role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding 
authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
Between January, 1999, and March, 2005, 937 carriers of 
Lynch syndrome in England, Finland, and Wales of 
1071 assessed started intervention in the CAPP2 study. 
Table 1 documents the characteristics of the 427 CAPP2 
participants randomly assigned to aspirin and the 
434 participants randomly assigned to placebo. Each 
group had approximately 25 months of intervention and a 
mean of more than 7 years’ follow-up post-inter vention. 
The distribution of time since recruitment was also 
similar between the groups (table 1); 58 (14%) of the 
aspirin group and 67 (15%) of the placebo group had no 
follow-up after the intervention phase, predominantly 
because of refusal to consent to long-term follow-up (61%) 
or loss to follow-up (34%; figure 1). Since randomisation, 
40 (9%) of 427 participants randomly assigned to aspirin 
developed colorectal cancer compared with 58 (13%) of 
434 allocated to placebo (table 1). When all Lynch syndrome 
cancers are included, 74 (17%) of 427 participants from 
the aspirin group had developed cancer compared with 
89 (21%) of 434 in the placebo group (table 1).
We present analyses of the combined information from 
the post-trial surveillance of participants for the first 
10 years across all centres with that collected for up to 
20 years from national cancer data registry data sources 
for England (58%), Finland (41%), and Wales (1%). 
Information on the separate analyses of these datasets 
can be found in the appendix. For completeness, the 
numbers are reported for the overall 10-year follow-up of 
all partici pants in the appendix (p 9) and for the 20-year 
follow-up involving participants in England, Finland, and 
Wales only in the appendix (p 12). The close alignment 
between data collected by the CAPP Centres in the first 
10 years of follow-up for England, Finland, and Wales 
and the information collected directly from national 
health data sources for the same time period are shown 
in the appendix (p 11). There was almost complete 
concordance in reporting of colorectal cancer diagnoses 
between the CAPP centre and the national sources; 
however, concordance for both non-colorectal cancer 
Lynch syndrome diagnoses and non-Lynch syndrome 
diagnoses was lower, most notably for Finland. These 
observations reflect the fact that most recruiting centres 
took responsibility for organising and reviewing bowel 
Aspirin (n=427) Placebo (n=434) Total (n=861)
Time in CAPP2 intervention study (months)* 25·0 
(12·5, 0·8–60·6)
25·4 
(14·2, 1·1–74·4)
25·2 
(13·4, 0·8–74.4)
Months between study entry and last known 
follow-up date*
120·4 
(63·3, 1·6–238·7)
116·3 
(63·7, 1·1–238·9)
118·4 
(63·5, 1·1–238·9)
Years between study entry and last known follow-up date
≤2 36 (8%) 42 (10%) 78 (9%)
>2 and ≤6 80 (19%) 87 (20%) 167 (19%)
>6 and ≤10 133 (31%) 144 (33%) 277 (32%)
>10 and ≤14 54 (13%) 43 (10%) 97 (11%)
>14 and ≤18 104 (24%) 101 (23%) 205 (24%)
>18 and ≤20 20 (5%) 17 (4%) 37 (4%)
Participants with first colorectal cancer
Since randomisation 40 (9%) 58 (13%) 98 (11%)
Within 2 years of randomisation 10 (2%) 10 (2%) 20 (2%)
More than 2 years from randomisation 30 (7%) 48 (11%) 78 (9%)
Participants with other Lynch syndrome cancers (excluding colorectal)
Since randomisation 36 (8%) 36 (8%) 72 (8%)
Within 2 years of randomisation 7 (2%) 9 (2%) 16 (2%)
More than 2 years from randomisation 29 (7%) 27 (6%) 56 (7%)
Participants with one or more Lynch syndrome cancers (including colorectal)
Since randomisation 74 (17%) 89 (21%) 163 (19%)
Within 2 years of randomisation 17 (4%) 19 (4%) 36 (4%)
More than 2 years from randomisation 57 (13%) 70 (16%) 127 (15%)
Types of extracolonic Lynch syndrome cancers
Brain 2 (<1%) 0 2 (<1%)
Stomach, duodenum 5 (1%) 6 (1%) 11 (1%)
Bile duct, pancreas 8 (2%) 3 (1%) 11 (1%)
Urinary† 7 (2%) 6 (1%) 13 (2%)
Ovarian 2 (<1%) 2 (<1%) 4 (<1%)
Endometrium–uterine 8 (2%) 17 (4%) 25 (3%)
Multiple sites 4 (1%) 2 (<1%) 6 (1%)
Participants with non-Lynch syndrome cancers
Since randomisation 36 (8%) 42 (10%) 78 (9%)
Within 2 years of randomisation 2 (<1%) 7 (2%) 9 (1%)
More than 2 years from randomisation 34 (8%) 35 (8%) 69 (8%)
*Data are mean (SD, range) or n (%). †Urinary cancers include ureter and kidney cancers.
Table 1: The whole CAPP2 cohort at 10 years plus England, Finland, and Wales registry data to 20 years
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surveillance while the spectrum of non-colorectal cancers 
challenged the capabilities of some centres to obtain 
complete information.
Intention-to treat analysis showed a reduced HR of 
0·65 (95% CI 0·43–0·97; p=0·035) for aspirin versus 
placebo (table 2; figure 2A; appendix p 16). Per-protocol 
analysis restricted to 509 participants who had achieved 
a minimum of 2 years on treatment showed a signifi-
cantly reduced HR of 0·56 (0·34–0·91; p=0·019; table 2; 
figure 2B; appendix p 16). Since some participants were 
diagnosed with multiple primary cancers, we did an 
incidence rate ratio analysis by means of negative binomial 
regression, which showed similar estimates for effect 
sizes and significance levels to the time to first colorectal 
cancer analysis (table 1).
Separate 10-year and 20-year analyses are reported in 
the appendix (pp 10, 13, 17–18) with similar findings with 
respect to effect sizes.
For non-colorectal Lynch syndrome cancers, neither 
intention-to-treat analysis (HR=0·94, 95% CI 0·59–1·50); 
p=0·81) nor per-protocol analysis (HR=0·75, 0·42–1·34; 
p=0·33; table 2) showed any significant effect of aspirin 
chemoprevention.
Separate 10-year and 20-year analyses are also reported in 
the appendix (pp 10, 13, 17–18); for this analysis, there is 
less consistency in the estimates between the analyses but 
there is no evidence of a cancer-prevention effect overall. 
Examination of individual anatomical sites is not feasible 
given the num bers of cases. However, for endometrial 
cancer, the most common Lynch syndrome cancer after 
the colo rectum, the observation of only seven cases 
among women on aspirin compared with 17 on placebo is 
suggestive but not conclusive of a protective effect of 
aspirin (HR=0·50, 95% CI 0·22–1·11; p=0·09; appendix 
p 19).
For all Lynch syndrome cancers, intention-to-treat 
analysis showed no significant effect (HR=0·76, 95% CI 
0·56–1·03; p=0·081) with similar results for the 
incidence rate ratio analysis. However, per-protocol 
analysis showed reduced risk among aspirin takers 
(HR=0·63, 0·43–0·92; p=0·018) with similar estimates 
and significance for the incidence rate ratio analysis 
(table 2; appendix p 16). Intention-to-treat and per-
protocol analysis for non-colorectal Lynch syndrome 
cancers are shown in the appendix (p 14) and the results 
for the separate 10-year and 20-year analyses are shown 
in the appendix (pp 17–18).
Although evidence of the beneficial effect of aspirin on 
cancer risk seems strongest for colorectal cancer, there is 
some evidence of a broader spectrum of activity2 so we 
examined the effect of aspirin on risk of all non-Lynch 
syndrome cancers (details in appendix p 14). There was 
no significant evidence of any effect of aspirin on non-
Lynch syndrome cancer risk (appendix p 10). In the data 
available for the second decade, there were five cancers 
in the aspirin group and 12 in the placebo group 
(HR=0·56, 95% CI 0·27–1·19; p=0·13; appendix p 14).
We investigated whether aspirin treatment affected 
the stage at which cancers were diagnosed. For the 
54 tumours for which Dukes’ stage information was 
available, there was no evidence of any stage differences 
between those randomly assigned to aspirin and to 
placebo (p=0·37; appendix p 15).
Discussion
Evidence accumulated over 30 years shows that frequent 
aspirin ingestion reduces cancer risk in the general 
population;15,16 analysis of data from observational studies, 
from trials with cardiovascular disease as the primary 
endpoint and from one trial with cancer as an endpoint, 
shows that the protective effect of aspirin takes 3–10 years 
to become apparent in the general population. Follow-up 
Hazard ratio† 
(95% CI)
p value Incidence rate 
ratio‡ (95% CI)
p value
Colorectal cancer
Intention-to-treat analysis (n=861, 98 events for hazard ratio analysis)
Aspirin vs placebo 0·65 (0·43–0·97) 0·035 0·58 (0·39–0·87) 0·0085
Per-protocol analysis§ (n=509, 67 events)
≥2 years’ placebo 1·0 ·· 1·0 ··
≥2 years’ aspirin 0·56 (0·34–0·91) 0·019 0·50 (0·31–0·82) 0·0057
Cumulative aspirin dose¶ (n=861, 98 events)
Units of 100 aspirin 0·98 (0·96–1·00) 0·079 0·98 (0·96–1·00) 0·032
Non-colorectal Lynch syndrome cancers
Intention-to-treat analysis (n=861, 72 events)
Aspirin vs placebo 0·94 (0·59–1·50) 0·81 1·05 (0·65–1·69) 0·84
Per-protocol analysis§ (n=509, 46 events)
≥2 years’ placebo 1·0 ·· 1·0 ··
≥2 years’ aspirin 0·75 (0·42–1·34) 0·33 0·87 (0·48–1·61) 0·67
Cumulative aspirin dose¶ (n=861, 72 events)
Units of 100 aspirin 0·98 (0·96–1·01) 0·20 0·99 (0·97-1·02) 0·50
All Lynch syndrome cancers
Intention-to-treat analysis (n=861, 163 events)
Aspirin vs placebo 0·76 (0·56–1·03) 0·081 0·75 (0·56–1·02) 0·065
Per-protocol analysis§ (n=509, 107 events)
≥2 years’ placebo 1·0 ·· 1·0 ··
≥2 years’ aspirin 0·63 (0·43–0·92) 0·018 0·65 (0·44–0·94) 0·022
Cumulative aspirin dose¶ (n=861, 163 events)
Units of 100 aspirin 0·98 (0·97–1·00) 0·033 0·98 (0·97–1·00) 0·040
All non-Lynch syndrome cancers
Intention-to-treat analysis (n=861, 78 events)
Aspirin vs placebo 0·81 (0·52–1·26) 0·34 0·79 (0·49–1·28) 0·34
Per-protocol analysis§ (n=509, 56 events)
≥2 years’ placebo 1·0 ·· 1·0 ··
≥2 years’ aspirin 0·81 (0·48–1·37) 0·43 0·71 (0·41–1·22) 0·21
Cumulative aspirin dose¶ (n=861, 78 events)
Units of 100 aspirin 0·99 (0·97–1·01) 0·43 0·99 (0·96–1·01) 0·32
*Adjusted for age and gender in all participants up to 10 years and up to 20 years in England, Finland, and Wales, 
randomly assigned to aspirin or placebo. †Adjusted for age at consent and gender. ‡Incidence rate ratio from negative 
binomial regression adjusted for age at consent and gender. §The threshold for 2 years’ intervention was consumption 
of more than 1400 aspirin tablets; rounded from a 2-year total of 1461 to allow for early scheduling of the exit 
colonoscopy or occasional missed dosage. ¶Units of 100 aspirin=total number of aspirin taken divided by 100.
Table 2: Cox proportional hazards and negative binomial regression analyses of cancer incidence*
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for 25 years and more in these studies showed no evi-
dence that the protective effect of aspirin had disappeared 
although there was evidence of a reduced effect of low 
doses in people of greater bodyweight.17
This analysis of data from people with Lynch syndrome 
recruited to the CAPP2 study shows that the protective 
effects of aspirin against colorectal cancer has persisted 
in this long-term analysis of up to 20 years’ follow-up. 
The CAPP2 study data were analysed at the end of the 
intervention, again when the first recruits reached their 
10-year follow-up and now when all participants reached 
10-years’ follow-up and some approached 20 years since 
recruitment. Colorectal cancer incidence began to diverge 
about 5 years after initiating aspirin treatment and this 
lower cancer incidence was maintained throughout 
the period of observation. This pattern is similar to that 
observed in the long-term follow-up of participants 
randomly assigned to aspirin in cardiovascular disease 
prevention trials.12,18
This long-term follow-up of cancer among patients 
confirms the view that 600 mg aspirin per day reduces the 
risk of colorectal cancer in patients with Lynch syndrome. 
While we had shown the protective effect in per pro-
tocol analysis (ie, restricting the focus to those who had 
regularly taken the aspirin during the intervention 
phase),11 this analysis confirms the extended effect both in 
the per-protocol group but, now, also in the intention-to-
treat analysis of all participants. As would be expected, the 
effect sizes in the intention-to-treat analysis are less 
extreme than the per-protocol analysis. The support from 
this intention-to-treat analysis reduces any concerns that 
the previous per-protocol finding was attributable, not to 
aspirin, but to an unidentified confounding factor which 
associated with non-adherence.
Whereas the evidence for CRC chemoprevention with 
aspirin for the genetically predisposed has increased, the 
evidence for prevention at the other anatomical sites 
relevant to Lynch syndrome has weakened.
The mechanism of action of aspirin in cancer prevention 
remains to be established; the beneficial effect of a range of 
NSAIDs in cancer prevention and the association between 
PIK3CA mutation and response of colorectal cancers to 
aspirin use in the Nurses’ Health Study19 point to a long-
term influence of the suppression of inflammation. The 
benefits seen in the Women’s Health Study8 followed use 
of alternate day low-dose aspirin, however, which is too low 
to suppress inflammation directly.
 The response to aspirin might reflect an effect on the 
viability of cells with malignant potential as suggested by 
studies in cell lines and mouse models.20,21 Salicylates in 
Figure 2: Time to first colorectal cancer and time to any Lynch syndrome cancer in all CAPP2 study participants followed up for 10 years and for 20 years in 
England, Finland, and Wales
Cox proportional hazards (HRs and 95% CIs) comparing those on aspirin vs those on placebo and depicted by Kaplan-Meier analysis (n=861). (A) Intention-to-treat 
analysis (n=427 aspirin, 434 placebo) by randomisation group. (B) Per-protocol analysis of all those achieving 2 years aspirin or placebo (n=259 aspirin; n=250 placebo). 
(C) Intention-to-treat analysis for any Lynch syndrome cancer. (D) Per-protocol analysis for any Lynch syndrome cancer. See appendix (p 16) for more details.
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plants modulate the apoptotic response to infection22 and 
might have a similar pro-apoptotic influence in the 
gut.23,24 Enhanced destruction of premalignant abnormal 
cells would offer an explanation for the long time-lag in 
response to aspirin intervention. The progressive decline 
in mitochondrial function, on which apoptosis is reliant, 
in the gut in old age might then contribute to the lesser 
response to aspirin chemoprevention in old age.25,26 
The widespread occurrence of aberrant colonic crypts, 
defective in mismatch repair, in Lynch syndrome27 
suggests that these might be the premalignant lesions 
that are suppressed or destroyed by long-term aspirin 
exposure, but this hypothesis remains to be tested. In 
addition, whether this occurs via enhanced apoptosis22 
or improved immune surveillance,28 or a combination of 
these and other mechanisms are important areas for 
future investigation.
It has been suggested that the results of the first follow-
up analysis might have reflected a temporary delay in 
progression of premalignant lesions rather than a true 
prevention of cancer. This is not supported by the 
continued separation of the cumulative incidence of 
colorectal cancer in the two treatment groups.
It is noteworthy that the effect on non-colorectal Lynch 
syndrome cancers was of similar magnitude to the lower 
intestinal effects in the 10-year data. The benefit in 
prevention of non-colorectal cancer tumours was not 
apparent in the data available for the second decade, 
suggesting that any preventive effect is not sustained. 
This is in keeping with the long-term follow up of the 
Women’s Health Study8 in which the effect of low dose 
aspirin, which appeared at 10 years, was evident for 
colorectal cancer only.
Weaknesses of this trial are that the geographically 
dispersed recruitment over a long period made 
collection of details of endoscopy difficult, so data on 
adenomas are incomplete and the current analysis is 
restricted to cancer as an endpoint. We were unable to 
comment on effect on mortality as the death rate in 
patients with Lynch syndrome undergoing surveillance 
is low; that would require a much larger study. Our 
study attempted to recruit patients with a confirmed, 
significant mutation in a mismatch repair gene. On that 
basis, we suggest that the finding is generalisable across 
all patients with Lynch syndrome. However, we do not 
have the power to indicate if particular subgroups (eg 
specific genes or mutations) have effect sizes different 
from the population overall. Side-effects of treatment 
were minimal in this relatively young population but 
are likely to be much higher if aspirin continues to be 
used into old age as illustrated by the ASPREE trial.29 
Conversely, the report of an overall anticancer benefit in 
people over 65 years of age30 is a reminder of the 
potential long-term benefits of aspirin as a means of 
therapeutic prevention of cancer in the wider population. 
It is noteworthy that 427 participants had 18 fewer 
colorectal cancers as a result of taking two aspirins a 
day for an average of 2·5 years, a number needed to 
treat of 24.
The CAPP2 study tested the effect of a single dose of 
aspirin (600 mg per day) and this study provides evidence 
that this dose was effective in long-term prevention of 
colorectal cancer. However, whether this is the optimum 
aspirin dose in respect of the balance between benefit 
(cancer risk reduction) and risk (gastrointestinal bleeding) 
remains to be determined. To address the issue of dosage, 
CaPP3 is a randomised dose non-inferiority trial of the 
dose of 600 mg daily, compared with 300 mg and 100 mg, 
delivered in a blinded fashion for 2 years followed by 
open-label treatment for a further 3 years and assessment 
of Lynch syndrome cancers annually thereafter.
With a minimum target of 1500 mismatch repair gene 
defect carriers, the study closed to recruitment on 
March 31, 2019, having randomly assigned a total of 
1882 Lynch syndrome gene carriers in the UK and four 
other countries. The first analysis of data from the 
randomised trial will be done in 2024.
In conclusion, the data reported here support the 
recommendation that adult carriers of a pathogenic 
mismatch repair gene defect (Lynch syndrome) should 
be advised that taking 600 mg aspirin daily for at least 
2 years significantly reduces the risk of a future cancer, 
bearing in mind that this effect does not become apparent 
for at least 4 years.
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